The FDA requires all makers of GLP-1 medications to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and possibly permanent vision loss. This decision follows a review of clinical trials and real-world data showing a higher incidence of NAION among GLP-1 users compared to other treatments. Although the condition is rare and a direct cause has not been confirmed, the FDA aims to inform patients of the potential risk. Manufacturers like Novo Nordisk and Eli Lilly have been contacted for comments.
Novo Nordisk, a key player in GLP-1 drugs, holds a market cap of $178.46 billion and a dividend yield of 4.46% on Pluang as of Nov 10, 2026 15:02 WIB. Eli Lilly, another major GLP-1 manufacturer, has a market cap of $1.21 trillion and a dividend yield of 0.51%, with a higher buy order activity at 65%. These figures highlight the significant market presence of both companies amid the FDA's recent warning on vision risks associated with their GLP-1 medications.
Novo Resources Corp. has released an updated corporate presentation outlining its strategic priorities, exploration results, and project advancements. The presentation highlights significant progress in Novo's gold exploration portfolio, including pr...
Novo Nordisk's Q3 results exceeded expectations, driven by a 53% increase in pill sales and strong net patient growth, dispelling fears of oral product cannibalization. The company is also reducing capital expenditures and expanding free cash flow, s...
Novo Nordisk A/S has been upgraded to a Strong Buy rating following robust third-quarter results and accelerating adoption of its Wegovy pill. The stock trades at a low valuation compared to pharma peers, supporting a value-driven investment case. An...
